1 of 1
Story summary
- In 2026, two outlicensing deals between Chinese drug makers and global partners exceeded US$1 billion.
- Sino Biopharmaceutical's deal with Sanofi is valued at up to US$1.53 billion.
- Antengene Corporation's agreement with UCB is worth about US$1.18 billion.
- As of February 24, 2026, China-originated outlicensing total reached US$52 billion from 41 transactions, after a record US$135.7 billion across 157 deals last year.
